Mon, May 1, 2023
Sun, April 30, 2023
Fri, April 28, 2023
Thu, April 27, 2023

Li Watsek Maintained (ASND) at Buy with Increased Target to $152 on, Apr 28th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-152-on-apr-28th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Li Watsek of Cantor Fitzgerald, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $142 to $152 on, Apr 28th, 2023.

Li has made no other calls on ASND in the last 4 months.



There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 1 agrees with Li's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, April 5th, 2023


These are the ratings of the 4 analyists that currently disagree with Li


  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $146 on, Wednesday, April 5th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $92 on, Tuesday, April 4th, 2023
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $163 on, Tuesday, January 17th, 2023
  • Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $177 on, Tuesday, January 3rd, 2023

Publication Contributing Sources